Breast Cancer Research and Treatment

, Volume 122, Issue 2, pp 483–488 | Cite as

Lack of an association between a functional polymorphism in the interleukin-6 gene promoter and breast cancer risk: a meta-analysis involving 25,703 subjects

  • Ke-Da Yu
  • Gen-Hong Di
  • Lei Fan
  • Ao-Xiang Chen
  • Chen Yang
  • Zhi-Ming Shao


The association between a single-nucleotide polymorphism (SNP) −174G > C (rs1800795) located in the IL-6 gene promoter and breast cancer risk is still controversial and ambiguous. We performed in this study a more precise estimation of the relationship by meta-analyzing the currently available evidence from literature. A total of 11 publications containing 12 studies including 10,137 cases and 15,566 controls were identified. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association in the codominant model, dominant model, and recessive model. When all the studies were pooled into the meta-analysis, there was no evidence showing a significant association between −174G > C and breast cancer risk (for CC vs. GG: OR = 1.024, 95% CI: 0.935–1.121; for GC vs. GG: OR = 1.008, 95% CI: 0.946-1.073; for dominant model: OR = 0.980, 95% CI: 0.857–1.121; and for recessive model: OR = 1.027, 95% CI: 0.944–1.117). In the subgroup analyses by ethnicity, no significant associations were observed in any genetic models. In summary, the present meta-analysis suggests that the functional polymorphism −174G > C within the IL-6 gene promoter is not associated with breast cancer risk. Identifying a unique SNP as a breast cancer risk predictor remains a very challenging task.


Interleukin-6 rs1800795 Breast cancer Susceptibility Meta-analysis 



This research is supported by grants from the National Basic Research Program of China (2006CB910501) and the National Natural Science Foundation of China (30971143, 30972936).


  1. 1.
    Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55:543–547CrossRefPubMedGoogle Scholar
  2. 2.
    Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293CrossRefPubMedGoogle Scholar
  3. 3.
    Mosser DM, Zhang X (2008) Interleukin-10: new perspectives on an old cytokine. Immunol Rev 226:205–218CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E (2008) Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol 44:1093–1099CrossRefPubMedGoogle Scholar
  5. 5.
    Howell WM, Rose-Zerilli MJ (2007) Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137:194S–199SPubMedGoogle Scholar
  6. 6.
    Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173CrossRefPubMedGoogle Scholar
  7. 7.
    Hirano T (1998) Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16:249–284CrossRefPubMedGoogle Scholar
  8. 8.
    Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20:15–26CrossRefPubMedGoogle Scholar
  9. 9.
    Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138–18144CrossRefPubMedGoogle Scholar
  10. 10.
    Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin Cancer Res 11:5718–5721CrossRefPubMedGoogle Scholar
  12. 12.
    Skerrett DL, Moore EM, Bernstein DS, Vahdat L (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23:208–214CrossRefPubMedGoogle Scholar
  13. 13.
    Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L (2005) Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16:253–260PubMedGoogle Scholar
  14. 14.
    Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gonzalez-Zuloeta Ladd AM, Arias Vasquez A, Witteman J, Uitterlinden AG, Coebergh JW, Hofman A, Stricker BH, van Duijn CM (2006) Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur J Epidemiol 21:373–376CrossRefPubMedGoogle Scholar
  16. 16.
    Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A (2007) Peroxisome proliferator-activated receptor-gamma2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28:427–434CrossRefPubMedGoogle Scholar
  17. 17.
    Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O (2007) Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28:1728–1733PubMedGoogle Scholar
  18. 18.
    Litovkin KV, Domenyuk VP, Bubnov VV, Zaporozhan VN (2007) Interleukin-6–174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol 29:295–298PubMedGoogle Scholar
  19. 19.
    Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 16:747–755CrossRefPubMedGoogle Scholar
  20. 20.
    Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB, Giuliano AR, Byers T (2008) Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity (Silver Spring) 16:339–347CrossRefGoogle Scholar
  21. 21.
    Slattery ML, Curtin K, Giuliano AR, Sweeney C, Baumgartner R, Edwards S, Wolff RK, Baumgartner KB, Byers T (2008) Active and passive smoking, IL6, ESR1, and breast cancer risk. Breast Cancer Res Treat 109:101–111CrossRefPubMedGoogle Scholar
  22. 22.
    Cherel M, Campion L, Bezieau S, Campone M, Charrier J, Gaschet J, Ricolleau G, Gouraud W, Charbonnel C, Jezequel P (2009) Molecular screening of interleukin-6 gene promoter and influence of −174G/C polymorphism on breast cancer. Cytokine 47:214–223CrossRefPubMedGoogle Scholar
  23. 23.
    Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG and Cox DG (2009) PTGS2 and IL6 Genetic Variation and Risk of Breast and Prostate Cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis (in press)Google Scholar
  24. 24.
    Wittke-Thompson JK, Pluzhnikov A, Cox NJ (2005) Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 76:967–986CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yu KD, Di GH, Fan L, Shao ZM (2009) Test of Hardy-Weinberg equilibrium in breast cancer case-control studies: an issue may influence the conclusions. Breast Cancer Res Treat 117:675–677CrossRefPubMedGoogle Scholar
  26. 26.
    Qiu LX, Chen B, Mao C, Zhan P, Yuan H, Xue K, Li J, Hu XC (2009) STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects. Breast Cancer Res Treat 118:599–603CrossRefGoogle Scholar
  27. 27.
    Yu KD, Di GH, Fan L, Wu J, Hu Z, Shen ZZ, Huang W, Shao ZM (2009) A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer. FASEB J 23:2274–2287CrossRefPubMedGoogle Scholar
  28. 28.
    Saha A, Bairwa NK, Ranjan A, Gupta V, Bamezai R (2003) Two novel somatic mutations in the human interleukin 6 promoter region in a patient with sporadic breast cancer. Eur J Immunogenet 30:397–400CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Ke-Da Yu
    • 1
    • 2
  • Gen-Hong Di
    • 1
    • 2
  • Lei Fan
    • 1
    • 2
  • Ao-Xiang Chen
    • 1
    • 2
  • Chen Yang
    • 1
    • 2
  • Zhi-Ming Shao
    • 1
    • 2
    • 3
  1. 1.Department of Breast SurgeryCancer Hospital/Cancer Institute, Fudan UniversityShanghaiPeople’s Republic of China
  2. 2.Department of OncologyShanghai Medical College, Fudan UniversityShanghaiPeople’s Republic of China
  3. 3.Institutes of Biomedical ScienceFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations